Plain-English translation of NCT06362694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether patients with advanced thyroid cancer (anaplastic thyroid cancer) that carries a specific genetic mutation can benefit from restarting dabrafenib and trametinib — drugs that target this mutation. You would be eligible if you previously responded to this medication, then your cancer grew despite chemotherapy, and researchers want to see if the same drugs might work again.
When advanced thyroid cancer grows despite chemotherapy, there are limited options left for patients. This trial is exploring whether restarting the original targeted medication could help some patients whose cancers initially responded to this treatment, potentially offering a new chance at controlling the disease.
You would take dabrafenib and trametinib tablets twice and once daily, respectively, continuing until your cancer progresses again or side effects become too difficult to manage. Before starting, you would have blood work, scans of your brain and body, and tests to check your tumor's genetic makeup. You would be monitored regularly with follow-up scans and lab work to see how the medication is working and to watch for side effects.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Russia